Targeting the extrinsic apoptosis pathway in cancer

Cytokine and Growth Factor Reviews

Volumn 19, Issue 3-4, 2008, Pages 325-331

  Ashkenazi, Avi ^a  

^a GENENTECH INC   (United States)

Author keywords

Apoptosis; Caspases; Hematologic neoplasms; p53 gene; Proapoptotic receptor agonists; Solid tumors

Indexed keywords

ALANINE AMINOTRANSFERASE; APOMAB; APOPTOSIS LIGAND LIGAND 2 TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND FUSION PROTEIN; CASPASE; DEATH RECEPTOR 4; GEMCITABINE; HUMAN MONOCLONAL ANTIBODY; HYBRID PROTEIN; IRINOTECAN; PROTEIN BAK; PROTEIN BAX; RECOMBINANT PROTEIN; RITUXIMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; COLORECTAL CANCER; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; GENE INACTIVATION; HUMAN; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIDE EFFECT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; HEMATOLOGIC NEOPLASMS; HUMANS; MICE; NEOPLASMS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 44749085513     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2008.04.001     Document Type: Article

References (30)

1. American Cancer Society. Cancer facts and figures 2006. Atlanta: American Cancer Society, 2006. Also available at: http://www.cancer.org/docroot/stt/stt_0.asp; Accessed January 21, 2007.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
3. Clarke C.A., and Glaser S.L. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 94 (2002) 2015-2023
4. Skarin A.T., and Dorfman D.M. Non-Hodgkin's lymphomas: current classification and management. CA Cancer J Clin 47 (1997) 351-372
5. Horning S.J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20 (1993) 75-88
6. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
7. Nicholson D.W. From bench to clinic with apoptosis-based therapeutic agents. Nature 407 (2000) 810-816
8. Lee J.M., and Bernstein A. Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev 14 (1995) 149-161
9. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2 (2002) 420-430
10. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
11. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., and Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12 (2000) 611-620
12. Kischkel F.C., Lawrence D.A., Tinel A., LeBlanc H., Virmani A., Schow P., et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 276 (2001) 46639-46646
13. LeBlanc H., Lawrence D., Varfolomeev E., Totpal K., Morlan J., Schow P., et al. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8 (2002) 274-281
14. Lavrik I.N., Golks A., and Krammer P.H. Caspases: pharmacological manipulation of cell death. J Clin Invest 115 (2005) 2665-2672
15. Ashkenazi A., Pai R.C., Fong S., Leung S., Lawrence D.A., Marsters S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104 (1999) 155-162
16. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5 (2005) 876-885
17. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R., et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6 (2000) 564-567
18. Qin J., Chaturvedi V., Bonish B., and Nickoloff B.J. Avoiding premature apoptosis of normal epidermal cells. Nat Med 7 (2001) 385-386
19. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7 (2001) 383-385
20. Ganten T.M., Koschny R., Sykora J., Schulze-Bergkamen H., Büchler P., Haas T.L., et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12 (2006) 2640-2646
21. Hao C., Song J.H., Hsi B., Lewis J., Song D.K., Petruk K.C., et al. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 64 (2004) 8502-8506
22. Kelley S.K., and Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 4 (2004) 333-339
23. Jin H., Yang R., Fong S., Totpal K., Lawrence D., Zheng Z., et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 64 (2004) 4900-4905
24. Hylander B.L., Pitoniak R., Penetrante R.B., Gibbs J.F., Oktay D., Cheng J., et al. The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice. J Transl Med 3 (2005) 22-35
25. Daniel D., Yang B., Lawrence D.A., Totpal K., Balter I., Lee W.P., et al. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 110 (2007) 4037-4046
26. Herbst R., Mendolson D., Ebbinghaus S., Gordon M.S., O'Dwyer P., Lieberman G., et al. A phase I safety and pharmacokinetic study in patients with advanced cancer treated with recombinant Apo2L/TRAIL, an apoptosis-inducing protein. J Clin Oncology 24 (2006) 3013
27. Yee L., Finale K., Dimick S., Calvert C., Robins J., Ing J., et al. A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low grade non-Hodgkin lymphoma. J Clin Oncol 25 Suppl. 18S (2007) 8078
28. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptic ligand Apo2L/TRAIL. Nat Med 13 (2007) 1070-1077
29. Adams C., Totpal K., Lawrence D., Masters S., Pitti R., Yee S., et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Diff 15 (2008) 751-761
30. Camidge D., Herbst R.S., Gordon M., Eckhardt S., Kurzroc R., Durbin B., et al. A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer. J Clin Oncol 25 Suppl. 18S (2007) 3582